Now offering group licensing for Rad Onc Oral Board Sim (version 1.3.3). If you are a residency program interested in group subscriptions for your residents, please contact me at [email protected]#RadOnc#ABR#MedEd
https://t.co/LBC0efSoz5
Studying for Rad Onc Oral Boards? Try out my app Rad Onc Oral Board Sim! It uses AI to generate unique cases and evaluates your spoken responses like a real board examiner. Let me know what you think! #RadOnc#ABR#MedEd
https://t.co/LBC0efSoz5
Happy to share this interactive contouring tutorial for dose-escalated RT in locally advanced pancreas ca, which follows our NRG consensus contouring atlas.
Thank you @johnroubil, @dsouzl, @aiims2738, & the @eContourRadOnc team for working on this case!
https://t.co/oxR785IKAD
Well done ! Where you at @doj
Fixing healthcare starts with you making the biggest insurers divest non insurance related businesses.
And
Taking a hard look at the largest healthcare systems with market dominance
Fellow chief resident John Roubil (@JohnRoubil) had an oral presentation on his working with @StJude attending Dr. Lucas looking at patterns of failure after pencil beam scanning proton therapy in pediatric patients #ASTRO25
@_EmilyHollis The coffee shop in the Sales Force tower - you walk through an urban park with exotic plants inside the building to get there!
https://t.co/aS0mN3opSO
We are so excited to have our new PGY2s join us this week!
Thanks for joining the crew, Lauren, Amanda, and @aleckonradmed. Happy to have you on board!
Do SRS margins really impact local control and/or radionecrosis when treating brain mets?
@Raj_Singh_MD@EricLehrer@joshuapalmermd
👇🏼👇🏼👇🏼
https://t.co/kOrBK9yNVC
New from @Raj_Singh_MD et al | Clinical outcomes following stereotactic radiosurgery for brain metastases from sarcoma primaries: An international multicenter analysis
https://t.co/eWGK0bFwuk
@OncoAlert#sarcoma#radonc
Full manuscript is now available in @JournalCancer - this is the largest series of SRS for sarcoma brain mets now showing excellent contemporary OS outcomes (~3 mons ⏭️ 11.2 mons), with histology/ECM and age as drivers of OS and LC respectively.
Excellent presentation @ACRORadOnc #ACRO2025 by @JohnRoubil on @IntRRF analysis on SRS for sarcoma brain metastases, showing favorable LC & OS. Leiomyosarcoma histologies and pts w/o progressive extracranial metastases had better OS